Skip to main content
. 2021 Apr 21;11:8666. doi: 10.1038/s41598-021-87939-9

Figure 4.

Figure 4

Immunomodulatory capacity of EVs in vitro and in vivo. (A) Gene expression of in vitro plated thioglycolate-stimulated peritoneal macrophages treated with or without EVs. NT no treatment. (B) Gene expression of in vitro plated thioglycolate-stimulated peritoneal macrophages treated with miR-10b mimic or miR scrambled control. (C) Schematic overview of the acute peritonitis mouse model. Mice received an intraperitoneal (i.p.) injection of zymosan (day 0) and then intravenous (i.v.) delivery of placebo (P) or EVs (E) (days 0 and 1). Animals were sacrificed on day 2 and peritoneal exudate collected for flow cytometry. Figure was generated using Microsoft PowerPoint (https://www.microsoft.com/en-us/microsoft-365/powerpoint). (D) Representative flow plots of peritoneal cells collected on day 2. (E) Quantification of CD11b + F4/80 + cells in (C). Results are depicted as mean ± SEM. Statistical significance was determined using 1-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05.